Last reviewed · How we verify
Amlodipine 2.5 mg
At a glance
| Generic name | Amlodipine 2.5 mg |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Hypertension in Young Adults Trial (PHASE2)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Calcium Channel Blocker in Myotonic Dystrophy Type 1 (PHASE1)
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine 2.5 mg CI brief — competitive landscape report
- Amlodipine 2.5 mg updates RSS · CI watch RSS
- Novartis portfolio CI